News Release(2022)

December 23, 2022

Marketing Authorization Approval in Japan for TAVALISSE® Tab. 100mg and 150mg, an Oral Spleen Tyrosine Kinase Inhibitor

December 19, 2022

Results of Phase 3 Clinical Study of Fostamatinib Conducted in Japan for Treatment of Immune Thrombocytopenia (R788-1301) Published in British Journal of Haematology

November 2, 2022

Licensing Agreement for GnRH Antagonist Linzagolix with Synmosa Biopharma Corporation in Taiwan

October 28, 2022

Notice Concerning Revisions to Financial Results Forecast

September 28, 2022

Difelikefalin New Drug Application Submitted in Japan for Treatment of Pruritus in Hemodialysis Patients

August 22, 2022

Notice on withdrawal of New Drug Application in the US of GnRH antagonist "Linzagolix"

July 27, 2022

Notice on the release by ObsEva, the licensee of "Linzagolix", GnRH antagonist

July 6, 2022

Kissei Initiates Phase III Clinical Trial for GnRH antagonist Linzagolix in Japanese Patients with uterine fibroids

June 17, 2022

Marketing authorization in Europe for GnRH antagonist Linzagolix

June 6, 2022

Launch of TAVNEOS® Capsules 10mg, a selective Complement C5a Receptor Antagonist

May 30, 2022

"CAROGRA® Tablets", Launched in Japan for Treatment of Ulcerative Colitis
－ The World-First Orally Available α4 Integrin Antagonist Come onto the Market －

April 27, 2022

Submission of New Drug Application for Fostamatinib, an oral spleen tyrosine kinase inhibitor, in Japan

April 25, 2022

Confirmation of Positive CHMP Opinion for GnRH Antagonist "Linzagolix" in Europe

April 22, 2022

Kissei Announces New President and COO

March 31, 2022

Results of Phase III Clinical Study of "CAROGRA® Tablets" Conducted in Japan for Treatment of Ulcerative Colitis (AJM300/CT3) Published in The Lancet Gastroenterology & Hepatology

March 28, 2022

"CAROGRA® Tablets", Approved in Japan for Treatment of Ulcerative Colitis - The World-First Orally Available α4 Integrin Antagonist -

February 7, 2022

Update on EU marketing authorisation process for "Linzagolix" for the Treatment of uterine fibroids

January 7, 2022

Positive Topline Results from Japanese Phase III Clinical Study (double-blind period) of Difelikefalin (MR13A9) in Hemodialysis Patients with Pruritus